Literature DB >> 18272304

Application and limitation of inhibitors in drug-transporter interactions studies.

Qing Wang1, Robert Strab, Paula Kardos, Chrissa Ferguson, Jibin Li, Albert Owen, Ismael J Hidalgo.   

Abstract

The objective of the present study was to investigate the reliability of transporter inhibitors in the elucidation of drug-transporter interactions when multiple transporters are present in a test system. The bidirectional permeabilities of digoxin, estrone-3-sulfate (E3S), and sulfasalazine, substrates of P-gp, BCRP/MRP2 and unspecified efflux transporters, respectively, were examined in Caco-2 and MDR-MDCK cells in the absence and presence of transporter inhibitors: CsA (P-gp), FTC (BCRP) and MK571 (MRP). Digoxin showed significant efflux ratios (ER) in both Caco-2 (ER=17) and MDR-MDCK (ER=120), whereas E3S and sulfasalazine only showed significant efflux in Caco-2 (ER=15 and 88, respectively) but not in MDR-MDCK cells (ER=1.1 and 1.3, respectively). CsA at 10 microM showed complete inhibition of digoxin efflux, partial inhibition of E3S efflux and no effect on sulfasalazine efflux. FTC and MK571 had different inhibitory effects on the efflux of these compounds. The present study shows evidence of the functional expression of multiple efflux transporter systems in Caco-2 cells. Although the use of Caco-2 cells and selected inhibitors of efflux transporters can provide useful mechanistic information on drug-drug interactions involving efflux transporters, the potential cross-reaction of inhibitors with multiple transporters makes it difficult to discern the role of individual transporters in drug transport or drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18272304     DOI: 10.1016/j.ijpharm.2007.12.024

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

1.  Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity.

Authors:  Swati Nagar; Jalia Tucker; Erica A Weiskircher; Siddhartha Bhoopathy; Ismael J Hidalgo; Ken Korzekwa
Journal:  Pharm Res       Date:  2013-09-10       Impact factor: 4.200

Review 2.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

3.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity.

Authors:  Yi-Ting Zhang; Yu-Qi Yu; Xiao-Xia Yan; Wen-Jie Wang; Xiao-Ting Tian; Le Wang; Wei-Liang Zhu; Li-Kun Gong; Guo-Yu Pan
Journal:  Acta Pharmacol Sin       Date:  2018-11-15       Impact factor: 6.150

5.  In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management.

Authors:  Megha Barot; Mitan R Gokulgandhi; Dhananjay Pal; Ashim K Mitra
Journal:  Exp Eye Res       Date:  2013-10-22       Impact factor: 3.467

6.  The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule.

Authors:  Sarah E Jenkinson; Git W Chung; Ellen van Loon; Nur S Bakar; Abigail M Dalzell; Colin D A Brown
Journal:  Pflugers Arch       Date:  2012-09-27       Impact factor: 3.657

7.  Functional characterization of Clonorchis sinensis sodium-bile acid co-transporter (CsSBAT) as a steroid sulfate transporter.

Authors:  Haneul Jung; Jeong Yeon Won; Yun-Kyu Park; Jin-Hee Han; Seok Ho Cha
Journal:  Parasitol Res       Date:  2021-11-26       Impact factor: 2.289

8.  The inhibitory effects of mitragynine on P-glycoprotein in vitro.

Authors:  Noradliyanti Rusli; Azimah Amanah; Gurjeet Kaur; Mohd Ilham Adenan; Shaida Fariza Sulaiman; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-02       Impact factor: 3.000

9.  Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion.

Authors:  Wei Yue; Koji Abe; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

10.  The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins.

Authors:  Carlos Luna-Tortós; Bernhard Rambeck; Uwe H Jürgens; Wolfgang Löscher
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.